170510 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
ANTI-CCR8 ANTIBODIES AND USES THEREOF
#2COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES
#3ANTIBODIES THAT BIND TO HUMAN CCR8
#4BIOMARKERS
#5SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID
#6ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
#7METHODS RELATING TO IMPAIRED RESPIRATORY HEALTH THERAPEUTICS
#8LIQUID BIOPSY FOR DIAGNOSIS OF EARLY OSTEOARTHRITIS
#9METHODS OF DETECTING PROSTATE CANCER
#10CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT
#11DEPLETING TUMOR-SPECIFIC TREGS
#12BIOMARKERS AND THEIR USE IN DIAGNOSING PARKINSON'S DISEASE, VITREORETINAL DISEASES, AND AGE-RELATED PATHOLOGIES
#13THERAPEUTIC BINDING MOLECULES
#143D BIOASSAYS TO MEASURE ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
#15ANTI-CCR8 ANTIBODIES AND USES THEREOF
#16BIOMARKER SIGNATURES INDICATIVE OF EARLY STAGES OF CANCER
#17METHODS FOR TREATING CELLULAR INFLAMMATION INDUCED BY AFB1
#18MARKERS OF AUTOIMMUNE DISEASES
#19THERAPEUTIC BINDING MOLECULES
#20METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESS
#21COMPOSITIONS AND METHODS INVOLVING ANTIBODY CONSTRUCTS
#22USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS
#23Biomarkers in Primary Biliary Cholangitis
#24ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
#25Methods of detecting prostate cancer
#26Identifying Risk of Cerebra Edema
#27Methods for detecting respiratory viral infection
#28METHODS FOR TREATING BLADDER CANCER
#29TOOLS AND METHODS FOR EXPRESSION OF MEMBRANE PROTEINS
#30SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID
#31AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS
#32S-LAYER PROTEIN 2D LATTICE COUPLED DETERGENT-FREE GPCR BIOELECTRONIC INTERFACES, DEVICES, AND METHODS FOR USE THEREOF
#33CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT
#34CXCR7 antagonists
#35Depleting tumor-specific tregs
#36CXCR3 as epigenetic marker for the identification of inflammatory immune cells, in particular CD8+ memory t cells
#37Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients
#38BIOMARKER FOR PREDICTING EFFECTIVENESS FOR AUTOIMMUNE DISEASE TREATMENT, DIAGNOSTIC KIT, AND USE FOR TREATMENT
#39Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#40IMPROVING ANTI-PD-1 CANCER THERAPY
#41METHODS AND KITS FOR EVALUATING CLINICAL OUTCOMES OF AUTOIMMUNE DISEASE
#42METHOD FOR DETERMINING A TISSUE INJURY AND REPAIR (TIAR) PROCESS ASSOCIATED WITH ABNORMAL FORMATION OF ENDOMETRIAL TISSUE
#43CANCERS EXPRESSING CCR5 AND METHODS OF TREATMENT OF SAME
#44Method for measuring a biomarker in a biological sample of an IPAF patient
#45Anti-FAM19A5 antibodies and uses thereof
#46AGENT FOR CONTROLLING CELLS CONSTITUTING CANCER MICROENVIRONMENT OR INFLAMMATORY MICROENVIRONMENT
#47CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT
#48DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#49Predicting responders to cyclophosphamide therapy
#50DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
#51TARGETING B CELLS TO ENHANCE RESPONSE TO IMMUNE CHECKPOINT BLOCKADE
#52CXCR7 antagonists
#53Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer
#54TREATING RESPIRATORY CONDITIONS
#55S-layer protein 2D lattice coupled detergent-free GPCR bioelectronic interfaces, devices, and methods for the use thereof
#56Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
#57Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
#58Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy
#59DEPLETING TUMOR-SPECIFIC TREGS
#60System for detecting infection in synovial fluid
#61Methods of treating acute myeloid leukemia
#62Methods of treating and/or preventing chronic obstructive pulmonary disease
#63Method for predicting prognosis of patient with cancer or inflammatory disease
#64Tools and methods for expression of membrane proteins
#65Method for identifying anti-cancer agents using an in vitro cell culture system that maintains cancer cell stemness
#66METHOD FOR QUANTIFYING MONOCLONAL ANTIBODY
#67Methods for Monitoring Responsiveness to Anti-SMAD7 Therapy
#68CXCR7 antagonists
#69Treating conditions associated with metabolic syndrome
#70Treating mental disorders
#71Treating cancer
#72Treating conditions associated with sepsis
#73Treating respiratory conditions
#74Treating multiple sclerosis
#75Human CDR-grafted antibody and antibody fragment thereof
#76Agent for controlling cells constituting cancer microenvironment or inflammatory microenvironment
#77NOVEL ANTI-CXCR4 ANTIBODY AND ITS USE FOR THE DETECTION AND DIAGNOSIS OF CANCER
#78Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
#79Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer
#80Method for diagnosing fibromyalgia syndrome, and kit therefor
#81Methods for determining susceptibility to coreceptor inhibitors
#82Blockade of CCL18 signaling via CCR6 as a therapeutic option in treating interstitial lung disease
#83CONJUGATES FOR TREATING INFLAMMATORY DISEASE AND IDENTIFICATION OF PATIENTS LIKELY TO BENEFIT FROM SUCH TREATMENT
#84Simultaneous Assay of Target and Target-Drug Binding
#85CXCR4 and ROBO1 expression as markers for autoimmune diabetes
#86CXCR7 antagonists
#87DETECTING CANCER WITH ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES
#88Methods of detecting prostate cancer
#89Human CDR-grafted antibody and antibody fragment thereof
#90Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis
#91DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#92DETERMINATION OF EFFICIENT TIME(S) FOR CHEMOTHERAPY DELIVERY
#93Methods of detecting and treating stem-cell containing solid tumors
#94CANCER PROGNOSTIC ASSAYS
#95Methods of monitoring responsiveness to anti-SMAD7 therapy
#96DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#97Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof
#98Anti-CXCR1 compositions and methods
#99BRAIN DAMAGE MARKER
#100BIOMARKER FOR CHRONIC INFLAMMATORY LUNG DISEASES
#101Tools and methods for expression of membrane proteins
#102Diagnosing and treating inflammatory diseases
#103Use of modulators of CCR5 in the treatment of cancer and cancer metastasis
#104Molecular determinants in the HIV-1 envelope associated with enhanced ability to enter CXCR4-expressing cells
#105USE OF CCR9, CCL25/TECK, AND INTEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
#106HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF
#107METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS
#108Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
#109COMPOSITION FOR DIAGNOSIS OF LIVER METASTASIS OF COLORECTAL CANCER AND THE USE THEREOF
#110DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#111Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
#112Novel Receptor Hetero-Dimers/-Oligomers
#113DETECTING CANCER WITH ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES
#114Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS
#115Method of using CCR3 binding agents to detect choroidal neovascularization
#116CCR3 inhibition for ocular angiogenesis and macular degeneration
#117Assay for analysis of free drug in samples
#118USE OF CCR9, CCL25/TECK, AND INTEGRIN ALPHA4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
#119USE OF CCR9, CCL25/TECK, AND INTEGRIN ALPHA4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
#120Human CDR-grafted antibody and antibody fragment thereof
#121METHOD FOR DETECTING INFLAMMATORY DISORDERS OF THE CENTRAL NERVOUS SYSTEM
#122ANTI-BRAK (CXCL14) HUMAN MONOCLONAL ANTIBODY AND USE THEREOF
#123Pharmaceutical peptides for the treatment of inflammatory diseases
#124METHODS FOR DIAGNOSING BIOLOGICAL SAMPLES CONTAINING STEM CELLS
#125Breast tumor treatment with anti-CXCR1 compositions
#126METHODS FOR SCREENING FOR MODULATORS OF CCRL2
#127Method for determining human immunodeficiency virus (HIV) coreceptor utilization by examining gp41 molecular determinants
#128Methods of using sIP-10, CD26 inhibitors and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections
#129Compositions and Methods for Therapy and Diagnosis of Cancer and Cancer Metastasis
#130Human CDR-grafted antibody and antibody fragment thereof
#131CCR3 inhibition for ocular angiogenesis and macular degeneration
#132ACNE LESION BIOMARKERS AND MODULATORS THEREOF
#133USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
#134CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion
#135Simultaneous assay of target and target-drug binding
#136Simultaneous assay of target and target-drug binding
#137Depleting tumor-specific tregs